Senvol International and a leading domestic pharmaceutical company announced that they started the construction of a globally advanced modular bioreactor manufacturing base in March 2025. The project adopts Senvol's patented "plant - equipment - process" three-dimensional collaborative design system, enabling the rapid deployment of clusters of 2000L disposable reactors. It is expected that after production starts in 2027, it will meet 30% of the global capacity demand.
Compared to the 18-month construction period for traditional stainless steel reactor plants, this project reduces the construction time to 9 months through standardized modules, doubling efficiency. The head of Senvol International's Life Sciences division stated that modular design not only significantly compresses delivery times but also achieves dual breakthroughs in process stability and cost controllability through full-chain localization.
This collaboration is seen as a significant milestone in achieving autonomous control over China's biomedical supply chain. According to industry data, Senvol International's previously constructed modular vaccine factory in Morocco has already achieved 70% local vaccine production coverage. Its "three-dimensional synergy" technology system demonstrates notable engineering advantages in the global biomanufacturing sector. After the project goes into operation, it is estimated to increase the efficiency of each biopharmaceutical production run by 40%, driving China's transition from a technology follower to a standard setter in the field of bioreactors.
Copyright © 2025 Senwo International
